Loading...
Market
How many countries will approve Sunlenca for HIV prevention by end of 2024?
2
Resolution / Starting Odds
0-10 • 25%
11-20 • 25%
21-30 • 25%
31+ • 25%
Official health regulatory bodies of respective countries
Story
Gilead's Sunlenca Shows 100% Efficacy in HIV Prevention Trial
Jun 20, 2024, 12:54 PM
Gilead Sciences announced that its twice-yearly injectable antiviral drug, lenacapavir, also known as Sunlenca, demonstrated 100% efficacy in preventing HIV infection in women during a late-stage trial. The study, which included over 2,000 women, showed that lenacapavir was more effective than the company's existing daily pill, Truvada. Researcher Joe Eron described the results as remarkable, noting that there were no infections among the participants. This trial is part of Gilead's most comprehensive and diverse HIV prevention program to date, underscoring the company's commitment to serving the needs of individuals seeking pre-exposure prophylaxis (PrEP).
View original story
Similar markets
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Fewer than 10 countries • 25%
10 to 20 countries • 25%
21 to 30 countries • 25%
More than 30 countries • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
More than 20 countries • 33%
10 to 20 countries • 34%
Less than 10 countries • 33%
0 • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
USA • 25%
UK • 25%
South Africa • 25%
Other • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
United States • 25%
South Africa • 25%
India • 25%
Other • 25%
Less than 50 countries • 25%
50 to 80 countries • 25%
81 to 120 countries • 25%
More than 120 countries • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61+ • 25%